http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ingporn Jiamset (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Ingporn Jiamset,Jitti Hanprasertpong 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.3
Objective: To evaluate the relationship between type 2 diabetes mellitus (DM) and oncologicaloutcomes in early stage cervical cancer patients who underwent radical surgical resection. Methods: Patients with early stage cervical cancer diagnosed between 2001 and 2014 wereretrospectively enrolled. We assessed the outcomes of 402 non-DM and 42 DM patients withcervical cancer. We tested the prognostic value of DM via Cox proportional hazard modeling. Results: Patients with DM were more likely to be older and overweight. In the DM group,20 and 22 patients were and were not taking metformin, respectively. The 5-year recurrencefreesurvival (RFS) and 5-year overall survival (OS) rate for the whole study population were88.49% and 96.34%, respectively. In the DM group, there was no evidence that metforminaffected the RFS (p=0.553) or the OS (p=0.429). In multivariate analysis, age (p=0.007),histology (p=0.006), and deep stromal invasion (p=0.007) were independent adverseprognostic factors for RFS. There was a borderline significant association of increased RFSwith DM (p=0.051). However, a time-varying-effect Cox model revealed that the DM wasassociated with a worse RFS (hazard ratio, 11.15; 95% CI, 2.00 to 62.08, p=0.022) after 5years. DM (p=0.008), age (p=0.009), and node status (p=0.001) were the only 3 independentprognostic factors for OS. Conclusion: Early stage cervical cancer patients with type 2 DM have a poorer oncologicaloutcome than patients without DM.
-
Jitti Hanprasertpong,Ingporn Jiamset,Alan Geater,Kittinun Leetanaporn,Thanarpan Peerawong 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.4
Objective: To determine the impact of time interval (TI) from radical hysterectomy with pelvicnode dissection (RHND) to adjuvant therapy on oncological outcomes in cervical cancer. Methods: The study included 110 stage IA2–IB1 cervical cancer patients who underwentRHND and adjuvant therapy. The patients were divided into 2 groups based on the cut-offpoints of TI of 4 and 6 weeks, respectively. The associations of TI and clinicopathologic factorswith oncological outcomes were evaluated using Cox proportional-hazards regression. Results: The median TI was 4.5 weeks. There were no statistical differences in 5-yearrecurrence-free survival (RFS) (89.2% vs. 81.0%, and 83.2% vs. 100.0%) or 5-year overallsurvival (OS) rates (90.9% vs. 97.2%, and 93.2% vs. 100.0%) between patients accordingto TI (≤4 vs. >4, and ≤6 vs. >6 weeks, respectively). Deep stromal invasion (p=0.037), andparametrial involvement (PI) (p=0.002) were identified as independent prognostic factorsfor RFS, together with the interaction between TI and squamous cell carcinoma histology(p<0.001). In patients with squamous cell carcinoma, a TI longer than 4 weeks wassignificantly associated with a worse RFS (hazard ratio [HR]=15.8; 95% confidence interval[CI]=1.4–173.9; p=0.024). Univariate analysis showed that only tumor size (p=0.023), and PI(p=0.003) were significantly associated with OS. Conclusion: Delay in administering adjuvant therapy more than 4 weeks after RHND in earlystage squamous cell cervical cancer results in poorer RFS.
-
Fear of cancer recurrence and its predictors among cervical cancer survivors
Jitti Hanprasertpong,Alan Geater,Ingporn Jiamset,Laaong Padungkul,Phongchawee Hirunkajonpan,Nartya Songhong 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.6
Objective: To identify the characteristics of fear of cancer recurrence (FCR) in cervical cancer survivors (CCSs) and investigate the relationship of FCR with demographic and medical characteristics, level of quality of life (QOL), and psychological distress. We also aimed to determine the predictors of FCR. Methods: The short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer Therapy-Cervical (FACT-Cx) questionnaire were administered to 699 CCSs who had complete treatment at Songklanagarind Hospital between 2006 and 2016. Analysis was performed to determine potential predictors associated with FCR. Results: Among the 12 items of the FoP-Q-SF, the 3 greatest fears were 1) worrying about what would happen to their family; 2) being afraid of pain; and 3) fear of disease progression. The prevalences of anxiety and depression disorder were 20.46% and 9.44%, respectively. CCSs who had FCR at the 5th quintile were more likely to have medical co-morbidities, low FACT-Cx scores in all domains and a high HADS scores (anxiety and depression disorder). Multivariate analysis showed that only anxiety disorder (odds ratio [OR]=4.99; p<0.001) and low FACT-Cx score (total) (OR=6.14; p<0.001) were identified as independent predictors for FCR at the 5th quintile. Conclusion: FCR is an important problem in cervical cancer which should be addressed during post-treatment care. Only anxiety disorder and low QOL were independently associated with high FCR
-
( Kulisara Nanthamongkolkul ),( Pacharadol Taweerat ),( Ingporn Jiamset ) 대한산부인과학회 2023 Obstetrics & Gynecology Science Vol.66 No.3
Objective To develop a nomogram for predicting 3-year overall survival (OS) and outcomes of surgically staged patients with uterine carcinosarcomas (UCS). Methods This retrospective study analyzed the clinicopathological characteristics, treatment data, and oncological outcomes of 69 patients diagnosed with UCS between January 2002 and September 2018. Significant prognostic factors for OS were identified and integrated to develop a nomogram. Concordance probability (CP) was used as a precision measure. The model was internally validated using bootstrapping samples to correct overfitting. Results The median follow-up time was 19.4 months (range, 0.77-106.13 months). The 3-year OS was 41.8% (95% confidence interval [CI], 29.9-58.3%). The International Federation of Gynecology and Obstetrics (FIGO) stage and adjuvant che motherapy were independent factors for OS. The CP of the nomogram integrating with body mass index (BMI), FIGO stage, and adjuvant chemotherapy was 0.72 (95% CI, 0.70-0.75). In addition, the calibration curves for the probability of 3-year OS demonstrated good agreement between the nomogram-predicted and observed data. Conclusion The established nomogram using BMI, FIGO stage, and adjuvant chemotherapy accurately predicted the 3-year OS of patients with UCS. The nomogram was useful for patient counselling and deciding on follow-up strategies.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
